Top-News

Ideaya Bioscience Aktie News

Aktie
WKN:  A2PJPB ISIN:  US45166A1025 US-Symbol:  IDYA Branche:  Biotechnologie Land:  USA
35,72 $
-0,29 $
-0,81%
30,684 € 21:12:50 Uhr
Depot/Watchlist
Marktkapitalisierung *
2,42 Mrd. €
Streubesitz
-
KGV
-8,18
neu: Nachhaltigkeits-Score
22 %
Index-Zuordnung
-

Ideaya Bioscience News

29.08.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
25.08.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events PR Newswire
18.08.25 - PR Newswire
IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025
IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025 PR Newswire
05.08.25 - PR Newswire
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire
01.08.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
24.07.25 - PR Newswire
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma PR Newswire
23.07.25 - PR Newswire
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy PR Newswire
22.07.25 - PR Newswire
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-​in-Class ...
21.07.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event PR Newswire
27.06.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
02.06.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events PR Newswire
30.05.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
06.05.25 - PR Newswire
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire
06.05.25 - PR Newswire
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
IDEAYA Biosciences Announces US FDA IND-​Clearance for IDE849, a Potential First-​in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors PR Newswire
28.04.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events PR Newswire
25.04.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
14.04.25 - PR Newswire
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma PR ...
10.04.25 - PR Newswire
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-​Deletion Urothelial Cancer PR Newswire
01.04.25 - PR Newswire
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events PR Newswire
31.03.25 - PR Newswire
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »